NOTCH is a highly attractive therapeutic target, pursued by a number of pharma companies, with clinical efficacy, “proof of concept” already achieved. NOTCH inhibitors were involved in major Pharma transactions (e.g. AstraZeneca, Celgene, GSK. AbbVie recently acquired StemCentrx for 10 billion US$).
A number of Pharma companies have ongoing NOTCH R&D programs, demonstrating the high interest of the industry, creating an attractive acquisition market, as many companies do not have a NOTCH inhibitor in their portfolio yet. With over 250´000 patients annually diagnosed for NOTCH dependent disease in hematological malignancies, lymphoma and solid tumour oncology indications, treatment of NOTCH driven cancers is an unmet medical need with no approved targeted therapy available. Based on incidence in multiple indications, the market potential for NOTCH inhibitors is estimated to exceed CHF 10 billion and CB-103 sales projections exceed CHF 1 billion, if developed in multiple indications.
CB-103 has the potential to become a first-in-class drug with unique properties, unrivalled by the competition. Managed by an experienced management team with a clear strategic focus on value creation in early stage clinical development, Cellestia is looking for future investors, partnerships or licensors to enable the clinical development of CB-103 towards proof-of-concept in phase II clinical development.